MELOXICAM- meloxicam tablet Aphena Pharma Solutions - Tennessee, LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MELOXICAM TABLETS USP. safely and effectively. See full prescribing information for MELOXICAM TABLETS USP.

MELOXICAM Tablets USP., for oral use

Initial U.S. Approval: 2000

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

See full prescribing information for complete boxed warning.

- Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1)
- Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1)
- NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2)

RECENT MAJOR CHANGES
Boxed Warning
5/2016
Indications and Usage, Juvenile Rheumatoid Arthritis (JRA)
Pauciarticular and Polyarticular Course (1.3) 6/2016
Dosage and Administration, General Dosing Instructions (2.1) 6/2016
Dosage and Administration, Juvenile Rheumatoid Arthritis (JRA)
Pauciarticular and Polyarticular Course (2.4) 6/2016
Warnings and Precautions, Cardiovascular Thrombotic
Events (5.1) 5/2016
Warnings and Precautions, Heart Failure and Edema (5.5) 5/2016
INDICATIONS AND USAGE
Meloxicam tablets are a non-steroidal anti-inflammatory drug indicated for: (1)
Osteoarthritis (OA) (1.1)
Rheumatoid Arthritis (RA) (1.2)
 Juvenile Rheumatoid Arthritis (JRA) in patients who weigh ≥60 kg (1.3)
DOSAGE AND ADMINISTRATION
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (2.1)
• OA (2.2) and RA (2.3):
Starting dose: 7.5 mg once daily

• IRA (2.4): 7.5 mg once daily in children ≥60 kg

Meloxicam Tablets are not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same (2.6)

------DOSAGE FORMS AND STRENGTHS ------

• Meloxicam Tablets USP: 7.5 mg and 15 mg (3)

Dose may be increased to 15 mg once daily

------ CONTRAINDICATIONS

• Known hypersensitivity to meloxicam or any components of the drug product (4)

- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4)
- In the setting of CABG surgery (4)

..... WARNINGS AND PRECAUTIONS

- <u>Hepatotoxicity</u>: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (5.3)
- <u>Hypertension</u>: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure (5.4, 7)
- <u>Heart Failure and Edema</u>: Avoid use of Meloxicam in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (5.5)
- <u>Renal Toxicity</u>: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of <u>Meloxicam</u> in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (5.6)
- Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs (5.7)
- <u>Exacerbation of Asthma Related to Aspirin Sensitivity</u>: Meloxicam is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (5.8)
- <u>Serious Skin Reactions</u>: Discontinue Meloxicam at first appearance of skin rash or other signs of hypersensitivity (5.9)
- <u>Premature Closure of Fetal Ductus Arteriosus</u>: Avoid use in pregnant women starting at 30 weeks gestation (5.10, 8.1)
- <u>Hematologic Toxicity</u>: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (5.11, 7)

----- ADVERSE REACTIONS -----

- Most common (≥5% and greater than placebo) adverse events in adults are diarrhea, upper respiratory tract infections, dyspepsia, and influenza-like symptoms (6.1)
- Adverse events observed in pediatric studies were similar in nature to the adult clinical trial experience (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact XLCare Pharmaceuticals, Inc. at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

.....DRUG INTERACTIONS

- <u>Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs)</u>: Monitor patients for bleeding who are concomitantly taking Meloxicam with drugs that interfere with hemostasis. Concomitant use of Meloxicam and analgesic doses of aspirin is not generally recommended (7)
- <u>ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers</u>: Concomitant use with Meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure (7)
- <u>ACE Inhibitors and ARBs</u>: Concomitant use with Meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function (7)
- <u>Diuretics</u>: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects (7)

----- USE IN SPECIFIC POPULATIONS -----

- <u>Pregnancy</u>: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation (5.10, 8.1)
- <u>Infertility</u>: NSAIDs are associated with reversible infertility. Consider withdrawal of Meloxicam in women who have difficulties conceiving (8.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 2/2021

FULL PRESCRIBING INFORMATION: CONTENTS*
WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL
EVENTS

1 INDICATIONS AND USAGE

- 1.1 Osteoarthritis (OA)
- 1.2 Rheumatoid Arthritis (RA)
- 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

2 DOSAGE AND ADMINISTRATION

- 2.1 General Dosing Instructions
- 2.2 Osteoarthritis
- 2.3 Rheumatoid Arthritis
- 2.4 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course
- 2.5 Renal Impairment
- 2.6 Non-Interchangeability with Other Formulations of Meloxicam

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Cardiovascular Thrombotic Events
- 5.2 Gastrointestinal Bleeding, Ulceration, and Perforation
- 5.3 Hepatotoxicity
- 5.4 Hypertension
- 5.5 Heart Failure and Edema
- 5.6 Renal Toxicity and Hyperkalemia
- 5.7 Anaphylactic Reactions
- 5.8 Exacerbation of Asthma Related to Aspirin Sensitivity
- 5.9 Serious Skin Reactions
- 5.10 Premature Closure of Fetal Ductus Arteriosus
- 5.11 Hematologic Toxicity
- 5.12 Masking of Inflammation and Fever
- 5.13 Laboratory Monitoring

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Post Marketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Osteoarthritis and Rheumatoid Arthritis
- 14.2 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

- Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1)].
- Meloxicam tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)].

Gastrointestinal Bleeding, Ulceration, and Perforation

• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

1.1 Osteoarthritis (OA)

Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)].

1.2 Rheumatoid Arthritis (RA)

Meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)].

1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

Meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients who weigh \geq 60 kg [see Dosage and Administration (2.4) and Clinical Studies (14.2)].

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Instructions

Carefully consider the potential benefits and risks of Meloxicam tablets and other treatment options before deciding to use Meloxicam tablets. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].

After observing the response to initial therapy with Meloxicam tablets, adjust the dose to suit an individual patient's needs.

In adults, the maximum recommended daily oral dose of Meloxicam tablets is 15 mg regardless of formulation. In patients with hemodialysis, a maximum daily dosage of 7.5 mg is recommended [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

Meloxicam tablets may be taken without regard to timing of meals.

2.2 Osteoarthritis

For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of Meloxicam tablets is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

2.3 Rheumatoid Arthritis

For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of Meloxicam tablets is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

2.4 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of Meloxicam tablets is 7.5 mg once daily in children who weigh \geq 60 kg. There was no additional benefit demonstrated by increasing the dose above 7.5 mg in clinical trials.

Meloxicam tablets should not be used in children who weigh <60 kg.

2.5 Renal Impairment

The use of Meloxicam tablets in subjects with severe renal impairment is not recommended.

In patients on hemodialysis, the maximum dosage of Meloxicam tablets is 7.5 mg per day [see Clinical Pharmacology (12.3)].

2.6 Non-Interchangeability with Other Formulations of Meloxicam

Meloxicam tablets have not shown equivalent systemic exposure to other approved formulations of oral meloxicam. Therefore, Meloxicam tablets are not interchangeable with other formulations of oral meloxicam product even if the total milligram strength is the same. Do not substitute similar dose strengths of Meloxicam tablets with other formulations of oral meloxicam product.

3 DOSAGE FORMS AND STRENGTHS

Meloxicam Tablets USP:

- 7.5 mg: Light yellow, round flat beveled edge tablet with "T" on one side and "152" on the other side.
- 15 mg: Light yellow, capsule shaped biconvex tablet with "T" on one side and "153" on the other side.

4 CONTRAINDICATIONS

Meloxicam tablets are contraindicated in the following patients:

- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [see Warnings and Precautions (5.7, 5.9)]
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7, 5.8)]
- In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)]

5 WARNINGS AND PRECAUTIONS

5.1 Cardiovascular Thrombotic Events

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.

To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as meloxicam, increases the risk of serious gastrointestinal (GI) events [see Warnings and Precautions (5.2)].

Status Post Coronary Artery Bypass Graft (CABG) Surgery

Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial

infarction and stroke. NSAIDs are contraindicated in the setting of CABG [see Contraindications (4)].

Post-MI Patients

Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

Avoid the use of Meloxicam in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If Meloxicam is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

5.2 Gastrointestinal Bleeding, Ulceration, and Perforation

NSAIDs, including meloxicam, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.

Risk Factors for GI Bleeding, Ulceration, and Perforation

Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.

Strategies to Minimize the GI Risks in NSAID-treated patients:

- Use the lowest effective dosage for the shortest possible duration.
- Avoid administration of more than one NSAID at a time.
- Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs.
- Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.
- If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue Meloxicam until a serious GI adverse event is ruled out.
- In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor

patients more closely for evidence of GI bleeding [see Drug Interactions (7)].

5.3 Hepatotoxicity

Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported.

Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including meloxicam.

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flulike" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue Meloxicam immediately, and perform a clinical evaluation of the patient [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

5.4 Hypertension

NSAIDs, including Meloxicam, can lead to new onset or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [see Drug Interactions (7)].

Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.

5.5 Heart Failure and Edema

The Coxib and traditional NSAID Trialists' Collaboration meta analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of meloxicam may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [see Drug Interactions (7)].

Avoid the use of Meloxicam in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If Meloxicam is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

5.6 Renal Toxicity and Hyperkalemia

Renal Toxicity

Long-term administration of NSAIDs, including Meloxicam, has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

The renal effects of Meloxicam may hasten the progression of renal dysfunction in patients with preexisting renal disease. Because some Meloxicam metabolites are excreted by the kidney, monitor patients for signs of worsening renal function.

Correct volume status in dehydrated or hypovolemic patients prior to initiating Meloxicam. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of Meloxicam [see Drug Interactions (7)].

No information is available from controlled clinical studies regarding the use of Meloxicam in patients with advanced renal disease. Avoid the use of Meloxicam in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If Meloxicam is used in patients with advanced renal disease, monitor patients for signs of worsening renal function [see Clinical Pharmacology (12.3)].

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.

5.7 Anaphylactic Reactions

Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma [see Contraindications (4) and Warnings and Precautions (5.8)].

Seek emergency help if an anaphylactic reaction occurs.

5.8 Exacerbation of Asthma Related to Aspirin Sensitivity

A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, Meloxicam is contraindicated in patients with this form of aspirin sensitivity [see Contraindications (4)]. When Meloxicam is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.

5.9 Serious Skin Reactions

NSAIDs, including meloxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis

(TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of Meloxicam at the first appearance of skin rash or any other sign of hypersensitivity. Meloxicam is contraindicated in patients with previous serious skin reactions to NSAIDs [see Contraindications (4)].

5.10 Premature Closure of Fetal Ductus Arteriosus

Meloxicam may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including Meloxicam, in pregnant women starting at 30 weeks of gestation (third trimester) [see Use in Specific Populations (8.1)].

5.11 Hematologic Toxicity

Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with Meloxicam has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including Meloxicam, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].

5.12 Masking of Inflammation and Fever

The pharmacological activity of Meloxicam in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.

5.13 Laboratory Monitoring

Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [see Warnings and Precautions (5.2, 5.3, 5.6)].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Cardiovascular Thrombotic Events [see Boxed Warning and Warnings and Precautions (5.1)]
- GI Bleeding, Ulceration, and Perforation [see Boxed Warning and Warnings and Precautions (5.2)]
- Hepatotoxicity [see Warnings and Precautions (5.3)]
- Hypertension [see Warnings and Precautions (5.4)]
- Heart Failure and Edema [see Warnings and Precautions (5.5)]
- Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.6)]
- Anaphylactic Reactions [see Warnings and Precautions (5.7)]
- Serious Skin Reactions [see Warnings and Precautions (5.9)]
- Hematologic Toxicity [see Warnings and Precautions (5.11)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults

Osteoarthritis and Rheumatoid Arthritis

The Meloxicam Phase 2/3 clinical trial database includes 10,122 OA patients and 1012 RA patients treated with Meloxicam 7.5 mg/day, 3505 OA patients and 1351 RA patients treated with Meloxicam 15 mg/day. Meloxicam at these doses was administered to 661 patients for at least 6 months and to 312 patients for at least one year. Approximately 10,500 of these patients were treated in ten placebo- and/or active-controlled osteoarthritis trials and 2363 of these patients were treated in ten placebo- and/or active-controlled rheumatoid arthritis trials. Gastrointestinal (GI) adverse events were the most frequently reported adverse events in all treatment groups across Meloxicam trials.

A 12-week multicenter, double-blind, randomized trial was conducted in patients with osteoarthritis of the knee or hip to compare the efficacy and safety of Meloxicam with placebo and with an active control. Two 12-week multicenter, double-blind, randomized trials were conducted in patients with rheumatoid arthritis to compare the efficacy and safety of Meloxicam with placebo.

Table 1a depicts adverse events that occurred in ≥2% of the Meloxicam treatment groups in a 12-week placebo- and active-controlled osteoarthritis trial.

Table 1b depicts adverse events that occurred in \geq 2% of the Meloxicam treatment groups in two 12-week placebo-controlled rheumatoid arthritis trials.

	Placako	Melacicam 7.5 mg daily	Metacicam 15 mg daily	Dictolerac 100 mg daily
No. of Patients	157	154	156	153
Gastrointestinal	17.2	20.1	17.3	26.1
Abdominal pain (transea	2.5	7.8	2.6	9.2
Dyspepsia	45	4.5	4.5	6.5
Ratuler pe	4.5	3.2	3.2	3.9
Nausea	3.2	8.0	3.8	7.2
Body as a Whele	3.00			
Accident household	1.9	4.5	3.2	2.6
Edema ¹	2.5	1.9	4.6	3.3
Fall	0.6	2.6	0.0	1.3
Influenza-like symptoms	5.1	4.5	5.8	2.6
Contral and Peripheral Nervous Bys Dizziness	3.2	2.6	3.8	2.0
Hoadache	10.2	7.3	8.3	5.9
Respiratory				
Pharyogitis	1.5	0.6	3.2	1.5
Upper respiratory tract infection	n 1.9	8.2	1.9	3.5
Skin	2.933	791243	75/95/5	.000
Rash ^a	2.5	2.6	0.6	2.0
WHO preferred terms edems, edema WHO preferred terms rash, rash cryth able 1b Adwerse Events (%) Oscar infertils Placebo- Controlled Trials	nematous, and rash	maculo papular leloalcam Patien	combined	
		Phase	7.5 mg daily	15 mg daily
No. of Patients		499	481	477
Gastrointestinal Disorders		14.1	18.9	16.6
Abdominal pain NOS:	11	0.6	2.9	2.3
Dymeptic signs and symp	lone"	3.8	5.8	4.0
tion next General Disorders and Administrati	on Sits Conditions	2.6	33	2.3
hthers-ye it es;	one continues	2.1	2.9	2.3
Intection and Intestations		-	5.0	
Upper Respiratory tract int unspecified?		tees 4.1	7.0	6.5
Nusculoskulotal and Connective Tis				9.9
Joint related signs and syr Hervous System Disorders	abeaus.	1.9	1.5	2.3
Headaches NOS* Sain and Seboulenesses Tissue Olos Rash NOS* MedORA high level term (proferra aggrovated, crustation, gastrointesti (Anyngita NOS, pharyngita NOS, si aggrovated, crustation, gastrointesti (Anyngita NOS, pharyngita NOS, si	ed farms): dyspepi nal irritation), uppe nustis NGS), joint looks (oint swelling	r respiratory trac related signs and é	infections path symptoms (art)	ogen unspecifi traigia, arthraig
Headaches NOS* Sain and Sabadheseass Transe Otos Rach NOS* MedDRA high level term (proform aggrowand, creatation, past-related) (anyugitis NOS, phanyugitis NOS, sis aggrowand, pietr creatation, puri of the MedDRA professor term chances, and he adheast events that occurred with anyulerin (5 months) in active-contro- table 2 Adverse Events (%) Occurring	ed fermst: dyspepi nai infation), uppe nusitis MOS), joint locion, joint swalling lominal pain MOS, in Melovicam in #24 illed osteoarthrifs tr	1.7 tic signs and sy resolitatory true objects and of theorea-like lines of patients treatials are presented	1.0 emptone (dysperinfections path symptoms (arti- is, hazdaches Wi ked short term (4 d in Table 2.	2.1 opela, dyspegi ogen unspecifi hralgia, arthralg 08, and rash NO i to 6 weeks) a
Headaches NOS! Skin and Sebadeseass Tissue Biss Rach NOS! MedCRA high level term (proform approved, creatalism, pastmintediii (lanying its NOS, phanying its NOS, sis approved, part creatalism, part all had the professor term hazaes, and he advance cerets that occurred with paytern (it months) is active-contro- table 2 Merece Events (%) Documin table 2 Merece Events (%) Documin	ed ferms): dyspepi nal initation), uppe nusitis NOS), joint locker, joint swelling ominal pain NOS, in Nelsoccarn in 224 led esteas thrifts to g in 22% of Melood	1.7 tio eigns and s r respiratory trac soluted signs and 0 thus not line c of patients from late are presente som Patients in 4	1.0 emptoms (dyses Inflections path symptoms (arti- ss, headaches Mi ed short term (4 in Table 2. it to 6 Weeks and	2.1 epole, dyspegi open unspecifi- tralgia, arthralg 38, and rash M3 i to 6 weeks) a 1 6 Month Activ
Headaches NOS! Skin and Sebadeseass Those 0 ice Rach NOS! MedCRA high level term (proform approved, creatalism, pastmintedir (languight NOS, phanyagitis NOS, sis approved, part creatalism, part all hadCRA professor term access, and the advance cents that occurred with pagistern (5 months) is active-contro- table 2 Advance Events (%) Occurring table 2 Advance Events (%) Occurring	ed terms): dyspepi nal infation), upper nasitis NOS), joint institu, joint seveling loominal pain NOS, in Melooteam In 22% iled esteamthrills to g in 22% of Melood 4-6 Weeks Costh	1.7 to eigns and s prespiratory trac solated signs and 0 distance-like liter of patients treat sam Patients in 4 rolled Trials	1.0 emptoms (dyses Infections path symptoms (arti- ss, headaches Mi ed short term (4 In Table 2. In 6 Weeks and 6 Meeth Cont	2.1 opple, dyspegi- oppn unspectfi- traigle, arthraig 06, and rash M i to 6 wooks) ar i 6 North Activ reflect Trials
Headaches NOS! Skin and Sebadeseass Those 0 ice Rach NOS! MedCRA high level term (proform approved, creatalism, pastmintedir (languight NOS, phanyagitis NOS, sis approved, part creatalism, part all hadCRA professor term access, and the advance cents that occurred with pagistern (5 months) is active-contro- table 2 Advance Events (%) Occurring table 2 Advance Events (%) Occurring	ed ferms): dyspepi nal initation), uppe nusitis NOS), joint locker, joint swelling ominal pain NOS, in Nelsoccarn in 224 led esteas thrifts to g in 22% of Melood	1.7 tic bigns and is respiratory translated signs and giftuenza-like lines, of settlents treat late are presented in a reflect lines. Welcoteam	1.0 emptoms (dyses Inflections path symptoms (arti- ss, headaches Mi ed short term (4 in Table 2. it to 6 Weeks and	2.1 opple, dyspegi- oppn unspectfi- traigle, arthraig 06, and rash M i to 6 wooks) ar i 6 North Activ reflect Trials
Headaches NOS! Sein and Sebadenesses Tissue Oice Rash NOS! MedCRA high level term (proform aggrounde, creatalism, gastrointechi (larying its NOS, pharying its NOS, sis aggressed, part creatables, part eli- med Rep referent term naceas, and the advised events that occurred with ong-term (it months) in active-contro- fable 2 Afrence Events (%) Occurring fable 2 Afrence Events (%) Occurring	od fermal dyspepi na imitation), upp nastis MOS, junt soon, junt seeding tominal pain MOS, in Melowicam in 22% ded ostacaments at glin 22% of Meloxi 4-6 Wester Carth Molecticam 7.6	1.7 tic bigns and is respiratory translated signs and giftuenza-like lines, of settlents treat late are presented in a reflect lines. Welcoteam	1.0 emptores (dyses infections path symptoms partials, has daches Model short term (4 tin Table 2.) 6 Meeth Cont. Melecicam	2.1 opple, dyspept oppn unspecifi- traigle, arthraig 06, and rash M0 i to 6 weeks) a i 6 North Activ relied Triefs Nelectoren 16
Headaches NOS! Skie and Selborianeaus Thoma Olice Rosh NOS! MedDRA high level term (proform aggrowand, credition, past-ninestill during its NOS, pharyagitis NOS, si aggrowand, paid consistent, joint dis MedDRA proformal term nacean, and The advance events that occurred with many-arm is mortiful in active worth folia 2 Atlantas Events (%) Decembra testinolised Osteonethritis Triats	od farms) dyscapled intrastic (dyscap) and intrastic (105), just inserts (105), just i	1.7 tic signs and is respiratory translated signs and it fluorea-les lines of sales are passante sam Patients in 4 molled Trials Networkers in 4 molled Trials Networkers in 5 mg daily	1.0 emptoms (dyse- infections path symptoms (art) symptoms (art) symptoms (art) symptoms (art) for faches No ed short term (4 in Table 2. it of Weeks and 6 Meeth Cont Melecicam 7.5 mg daily	2.1 spela, dyspeps open unspecifi bragia, arthralg 06, and rash NO 10 6 works) at 66 North Activ reflect Trials Nelloxicom 16 mg daily
Headaches NOS! Sain and Sahoulaseaus Trome Olde Rosh NOS! MedORA, high level form (preform aggressed, cractation, gastrointectin (during the NOS, pharyagith	od farmet dyscapi nat irritation, upper nastis NOS, junt issue, port awaiting cominal pain NOS, in Melowicam in 24% illed estacerimits to glin 29% of Melood 4-6 Wester Cont Melodicam 7.5 reg daily 8855	1.7 tic signs and is respiratory translated signs and it fluence—like time of the control of the	1.0 emptoms (dyse- infections path symptoms (arti- symptoms (a	2.1 apple, dyspept open unspecifi- braight, arthraig 05, and rash No. i to 6 weeks) a i 6 North Activ relied Trials Nellosteam 16 mg daily 306
Headaches NOS Sain and Selborianeaus Thoma Olice Rash NOS MedDRA, high level term (preferre aganwared, credition, gestrointech (langing its NOS, pharyagitis NOS, si agasewide, pid creations, gestrointech MedDRA preferred term: nausas, abd five adverse events that occurred with mad-parting if controlling in active worth relation of the selborian security in active and relation to the selborian selboria	ed farms): dyscepl nat irritation), upon mastis MSS, port mastis MSS, port mastis, mSS, port mastis, militation MSS, in Melowican in a 2% ded extendribution in glin a 2% of Meloxid 4-6 West Cest Melowican 7.5 mg delity 8935 11.8 2.7 0.8	1.7 In sign and to the sign and the si	1.0 Introduce (dysperiority particular) Introduce path symptomic	2.1 cooks, dycensycen region unspecification, and rash Miles and Miles and Miles and Advantage and Advantag
Headaches NOS! Sain and Selborianeaus Thoma Olice Rosh NOS! MedORA high level term (preferre aggrowated, creditation, postrointechi (larging lis NOS), pharyogis NOS, approvide, pint of MedORA preferred term: masses, abd medorates events that occurred with ang-term (if mentited) in active-contine table 2.Advance Events (%) Occurring controlled Octobranithatis Triats He. of Patients: Gastrienthestinal Abdominal pain	ed fermal, dyscept at inhabitori, upper matter MSS, porti assert, part asserting MSS, in Melandami MSS, in git a 2% of Melandami Molentami MSS, and Melandami MSS, and MSS, an	1.7 do sign and sign and sign and sign and sign and sign and signs and sign	1.0 infections (dyse) infections path infections path infections path infections path infections path infections (i.e., has eaches Microsoft for Table 2. It to 6 Weeks and 6 Meeticam Melecticam 1999 25.6 4.7	2.1 cooks, dycengroper unspecificating a principal of the facility of the following a principal of the following and the facility of the following and the facility of the fac
Headaches NOS* Sain and Sahadaseasa Trome Disco Rosh NOS* NecdRA high level form (preform aggravated, cractation, past-bidecel (daryights NOS, pharyights NOS, si aggravated, past-bidecel (daryights NOS, pharyights NOS, si aggravated, past-bidecel (daryights NOS, pharyights NOS, si aggravated, past consistency (daryights NOS, pharyights NOS, si aggravated, past- bidecel (daryights NOS, pharyights NOS, si aggravated, past- past-bidecel (daryights NOS, pharyights NOS, si aggravated (daryights NOS, pharyights NOS, si aggravated (daryights) Nos of Patients Opstreams Opstreams Dyspaps is	ed farms): dyscepl nat irritation), upon mastis MSS, port mastis MSS, port mastis, mSS, port mastis, militation MSS, in Melowican in a 2% ded extendribution in glin a 2% of Meloxid 4-6 West Cest Melowican 7.5 mg delity 8935 11.8 2.7 0.8	1.7 tic storms and its resistance that the selection of the control of the contro	1.0 Inflictions (dyses) inflictions path symptoms (artist symptoms (artist symptoms (artist symptoms (artist short)) (4 in Table 2 . 6 Meeth Cont Melectican 1984) 25.6 4.7 1.3 6.9 6.9	2.1 cotia, typonoso open unspecificacia, arthrale 56, and rash Mil 10 6 works) a 36 North Activ reflect Triefs NationScars 16 open ally 24.2 2.9 2.6 9.5
Headaches NOS Sain and Sahadanesson Trace Otto Rash NOS MedORA, high level term (preferre aggravated, creatation, postrointesti (darying to NOS), pharyingtis NOS, si aggravated, pict creation, postrointesti MedORA preferred term: massas, and modellar preferred term: modellar preferred term: modellar preferred modellar preferred Medomited path Carctipation Distribution Distribution Distribution Fatularies Fatularies	ed terms), dyscept all initiations, upper matter MSS, borth assert, part revenient mostly, for the search MSS, borth assert, part revenient part of the matter matt	1.7 tic stigms and its resolutions shall be selected to the selected stigms and districted stigms and districted stigms and districted stigms and districted stigms and selected stigms are posterior to reside a see posterior some Patients in - rooted Tristis Networks and Tristis Networks and Tristis Networks and Tristis Networks and Tristis 15 mg daily 256 18.0 2.3 1.2 7.4 0.4	1.0 Inflictions (dyses inflictions such inflictions such inflictions such inflictions such inflictions such inflictions in the such infliction in Table 2. In Table 3. In Table 4. In Table 3. In Table 4. In T	2.1 cotia, typopasionogen unspecification of the transpectification of the two tests at 16 North Active relief Triefs NationScars 16 mg daily 24.2 2.9 2.6 2.6 2.6 2.6 2.6
Headaches NOS Sain and Selectiones on Trans Otton Rash NOS MedORA high level term (preferre aggravated, creditation, post-intensit during tis NOS, pharyright NOS, aggravated, creditation, post-intensit during tis NOS, pharyright NOS, aggravated, pind of MedORA preferred term: nacesa, and medicate events that occurred with ang-term (if mention) in active-control catholise 2.threads Events (%) Occurring catholised Osteoarthritis Triats He, of Patients Gastrienthestinal Abdominal pain Constitution Dambez Dyspesia Fatulation Memos	ed ferms): dyscept at inhabitori, upper matter MSS, ton't assets MSS, ton't assets, part assetting MSS, in Melauctars in 28 side asteoder that is at g in 29 of Melauctar in 29 side asteoder that is at g in 29 of Melauctar MSS and MSS at g in 29 of Melauctar MSS and MSS at g in 29 of Melauctar 7.5 mg daily 8835 1.1.8 2.7 0.3 1.9 1.8 0.5 0.5	1.7 do sign and sign and sign and sign and sign and sign and signs and sign	1.0 emotions (dybus infections cathering to the control of the symptoms parties, has caches Mc dishort form (4 in Table 2	2.1 social, typoposis open unspecific origia, arthraig 06, and rash MC 15 6 works) at 16 North Activ molect finish Maleostean 16 mg daily 386 2.6 2.6 9.5 2.6 7.2
Headaches NOS* Sain and Sahoubaseaus Tromas Bloom Rosh NOS* MedORA, high level term (preferre aggressed, cractedian, pastrointech (during list NOS, pharyagits NOS, si aggressed, pint cractedian, pastrointech (during list NOS, pharyagits NOS, si aggressed, pint cractedian, ModORA preferred term; nascas, abo hadders expensed with any-serm (6 monthol in active-contre label 2 Advence Events (%) Documin Castrointech Lastrointech Lastrointech Abdominal path Constiguation Diarrhoe Dysoposia Ratulered Memiss Vorniting	ed terms), dyscept all initiations, upper matter MSS, borth assert, part revenient mostly, for the search MSS, borth assert, part revenient part of the matter matt	1.7 tic stigms and its resolutions shall be selected to the selected stigms and districted stigms and districted stigms and districted stigms and districted stigms and selected stigms are posterior to reside a see posterior some Patients in - rooted Tristis Networks and Tristis Networks and Tristis Networks and Tristis Networks and Tristis 15 mg daily 256 18.0 2.3 1.2 7.4 0.4	1.0 Inflictions (dyses inflictions such inflictions such inflictions such inflictions such inflictions such inflictions in the such infliction in Table 2. In Table 3. In Table 4. In Table 3. In Table 4. In T	2.1 cotia, typopasionogen unspecification of the transpectification of the two tests at 16 North Active relief Triefs NationScars 16 mg daily 24.2 2.9 2.6 2.6 2.6 2.6 2.6
Headaches NOS* Sain and Sahoubaneau Trome Oton Rosh NOS* NeedORA. high level form (preform aggrowated, cractation, past-bidecel (darying to NOS, pharying to NOS, si aggrowate, past or causation, past-bidecel (darying to NOS, pharying to NOS, si aggrowate, past or causation, political Modification of causation, political Modification of causation, political Modification of the causation of the past-series that occurred with providers (5 months) in active-contro- table 2 Atherica Events (%) Occurring cartholised Datacetteritis Trials No. of Patients Quatriothesimal Advantaging better Constitution Datacettering Dyspaps in Fatulicrop Months Vorniting Eody as a Whole Eody as a Whole	ed farms): dyscept all infraston), upon antition of the master AGS, point receiving the master AGS, point receiving and MGS, in MGS in MGS in MGS in MGS in MGS and MG	1.7 tic stops and is a resolution of satisfact and in the control of satisfact and in the control of satisfact and produced in the control of satisfact and present and the control of satisfact and present and the control of satisfact and present and the control of satisfact an	1.0 Inflictions (dyses inflictions such symptoms (artists symptoms (artists inflictions such symptoms (artists in Table 2). Infliction 2: Infliction 2: Infliction 3: Inflicion 3: Infliction 3: I	2.1 cotia, typonoso open unspecificación, archalo 6. and rash Mo 10.6 works) a 16 North Activ refled Triefs Nationated Triefs Nationated Triefs 24.2 2.9 2.6 9.5 2.6 7.2 2.6
Headaches NOS Sain and Sahoulaneaus Trome Oton Rosh NOS MedORA, high level term (preferre aggravated, creatation, postrointesti (dangel la NOS), pharyogith NOS, si aggravated, pict creations, postrointesti MedORA preferred term: masses, and modellar preferred term: modellar preferred term: modellar preferred modellar preferred modellar preferred Masses Venting Body as a Whole Accident household	ed ferms), dyscept at irritation, upper matter MSS, borth assets, most awards MSS, borth assets, mor traveling MSS, in Melavoican in 22 to make a second more matter to make a second more more more more more more more more	1.7 to stops and is a resolution of the control of	1.0 emptone (dyses) infections such infections in Table 2. In Table 2. In the 6 Weeks and 6 Meets Conf. Melecticam 7.5 mg daily 125.6 4.7 1.8 5.9 5.0 4.7 1.8 1.9 5.0 1.7 1.8 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9	2.1 cotia, typopasi open unspecification and as the second of the second
Headaches NOS Sain and Sahoulaneaus Thoma Oldo Rosh NOS MedORA high level term (preferre aggrowated, creditation, post-printedth (larging its NOS, pharyingth NOS, signovated, creditation, post-printedth MedORA preferred term inscens, and med adverse events that occurred with ang-term is mention; in active-contro- table 2 Adverse Events (%) Occurring Cartholised Catassanthritis Trials He, of Patients Gastrelatestinal Advantational path Constigution Disched Estatione Menses Veniting Eddy as a Whole Actidant thousanded Edama*	ed ferms): dyscept at inhabitori, upper matter MSS, torth assets MSS, torth assets, part assetting MSS, in Melaudcare in 29 to the matter MSS in Melaudcare in 29 to the matter MSS in Melaudcare 7.5 mg delity 8825 11.8 2.7 0.3 1.9 1.8 0.5 0.5 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6	1.7 do sign and sign consistency that or explainable of age in a consistency that or explainable of signs and of the consistency that of the consistency of published the consistency of published the consistency of the cons	1.0 emptone (dybus infections cathering to the property of the symptoms parties, has deches Mccd short form (4 in Table 2. in Table 2. it to 6 Weeks and Moleculean 7.5 mg daily 1998 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9 6.9	2.1 cota, typoposo open unspecificatiga, arthraig 16, and rash MC to 6 works) at 16 North Activ maled Triels Nationation 16 mg daily 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
Headaches NOS Sain and Sahoubaneau Trome Ottoe Resh NOS MedORA, high level term (preferre aggrowted, creatation, pastrointesti (darying to NOS), pharyingtis NOS, pharyingtis	ed ferms), dyscept at irritation, upper matter MSS, borth assets, most awards MSS, borth assets, mor traveling MSS, in Melavoican in 22 to make a second more matter to make a second more more more more more more more more	1.7 to stops and is a resolution of the control of	1.0 emptone (dyses) infections such infections in Table 2. In Table 2. In the 6 Weeks and 6 Meets Conf. Melecticam 7.5 mg daily 125.6 4.7 1.8 5.9 5.0 4.7 1.8 1.9 5.0 1.7 1.8 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9	2.1 cotia, typopasi open unspecification and as the second of the second
Headaches NOS* Sain and Sakoulanes on Trome Olico Rosh NOS* Med Har high level form (professor against red, created an, past minded (uring list NOS, protrymids NOS, singularity), created an, past minded (uring list NOS, protrymids NOS, singularity), created and exposered (uring list NOS, protrymids NOS, singularity), created and exposered (uring list Nos adverse exercise that occurred with any-serin (if months) in active-control folia 2 Adverse Events (s) Decuming Control (uring list Nos adverse exercise that occurred with any-serin (if months) in active-control (uring list Nos adverse). His of Patients Gastrointestinal Abdominal path Conscipation Districts Abdominal path Conscipation Districts Basicone Mennes Vorsating Red and Mennes Red and Mennes Print Control (uring list Nos adverse) Red and Partyment Mennes System System Print Control (uring list Nos adverse)	ed ferms): dyscept at inhabitation, upper matter MSS, to ril assets, part investigation of the matter MSS, to ril assets, part investigation of the matter matter in a 2% of Meladot and the set of the glin a 2% of Meladot and MSS, in migration of the migration o	1.7 do sign and sign consistency that or explainable of age in a consistency that or explainable of age in a consistency that of a consistency of additional area possession as are posterior to rotate of Trials Necleoteers 15 mg daily 2.8 daily 2.	1.0 emptone (dybus infections cathering to the property of the symptoms parties, has deches Mccd short form (4 in Table 2	2.1 cotals, syspensic popularización unicipals, arthrale paga, arthrale paga, arthrale paga, arthrale paga, arthrale paga, arthrale paga paga paga paga paga paga paga pag
Headaches NOS* Skin and Sahoubaseau Trome Oton Rosh NOS* MedORA, high level term (preferre aggressed, creatation, pathodetecti (during the NOS, pharyagith NOS, et aggressed, pint or excitation, pathodetecti (during the NOS, pharyagith NOS, et aggressed, pint or excitation, pathodetecti ModORA, preferred term; nassea, and hodorates that occurred with any-term (6 months) in active-contre table 2 Affectse Events (%) Decembly astrockled Oblassathetina Triats No. of Patients Gastrocknessinal Abdominal Abdominal Abdominal Diarrhos Dyspeps is Ratuleroe Mennes Verniting Body as a Whatie Actident Inscended Estama Phar Contral and Partiphend Mervices States (filtriness)	ed ferms): dyscept at intraction, upon at matter MSS, port installed in the matter MSS, port installed in the matter MSS in the matter MSS in	1.7 1.7 1.6 styre and is resistance to the selection of	1.0 Implementations (dyses) infections such symptoms (artistices such symptoms (artistices such symptoms (artistices)) in Table 2. In Table 2. In Table 2. In Table 2. In Table 3. In	2.1 cotals, dyspension open unspecification, archeals, archeals, and reals Mills 6 works) at 16 North Active reflect Triefs. National and and and additional archeals 24.2 2.9 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
Headaches NOS* Skin and Salvadaneses Transe Bloomer Resn NOS* Resn NOS* MedORA, high level form (preform against tod, creatables, past-piletes) (during the NOS, pharyagith NO	ed ferms): dyscept at inhabitation, upper matter MSS, to ril assets, part investigation of the matter MSS, to ril assets, part investigation of the matter matter in a 2% of Meladot and the set of the glin a 2% of Meladot and MSS, in migration of the migration o	1.7 do sign and sign consistency that or explainable of age in a consistency that or explainable of age in a consistency that of a consistency of additional area possession as are posterior to rotate of Trials Necleoteers 15 mg daily 2.8 daily 2.	1.0 emptone (dybus infections cathering to the property of the symptoms parties, has deches Mccd short form (4 in Table 2	2.1 cotals, syspensic popularización unicipals, arthrale paga, arthrale paga, arthrale paga, arthrale paga, arthrale paga, arthrale paga paga paga paga paga paga paga pag
Headaches NOS* Skin and Sahoubaseau Trome Oton Rosh NOS* MedORA, high level term (preferre aggressed, creatation, pathodetecti (during the NOS, pharyagith NOS, et aggressed, pint or excitation, pathodetecti (during the NOS, pharyagith NOS, et aggressed, pint or excitation, pathodetecti ModORA, preferred term; nassea, and hodorates that occurred with any-term (6 months) in active-contre table 2 Affectse Events (%) Decembly astrockled Oblassathetina Triats No. of Patients Gastrocknessinal Abdominal Abdominal Abdominal Diarrhos Dyspeps is Ratuleroe Mennes Verniting Body as a Whatie Actident Inscended Estama Phar Contral and Partiphend Mervices States (filtriness)	ed ferms): dyscept at intraction, upon at matter MSS, port installed in the matter MSS, port installed in the matter MSS in the matter MSS in	1.7 1.7 1.6 styre and is resistance to the selection of	1.0 Implementations (dyses) infections such symptoms (artistices such symptoms (artistices such symptoms (artistices)) in Table 2. In Table 2. In Table 2. In Table 2. In Table 3. In	2.1 cotals, dyspension open unspecification, archeals, archeals, and reals Mills 6 works) at 16 North Active reflect Triefs. National and and and additional archeals 24.2 2.9 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
Headaches NOS Sain and Sahouhaneau Dose Brown Rosh NOS Rosh NOS MedORA, high level term (preferre aggrovated, creditation, pastrointech (dangel to NOS, phanyagith NOS, pha	ed terms): dyscept at irritation; upper antition (St.), borth assets, part assetting (St.), borth assets, part assets (St.), borth assets (St.	1.7 to stops and is resolutioner than resolutioner than resolutioner than resolutioner than solution signs and of the resolution of published that are presented as are presented in the major than to make the resolution of the r	1.0 emptone (dyses) infections such infections in Table 2. In the SWeeks and Sweeks and Melecticam 7.3 mg daily 126.6 4.7 1.8 6.9 2.0 4.7 1.8 0.8 2.4 2.6 2.4 2.5 5.6	2.1 cota, typoposo open unspecification and as the second of the second
Headaches NOS* Sain and Sahoubaseaus Tromas Bloom Rosh NOS* MedDRA high level form (preferre aggressive), created an, pathodrechi, chrysig lis NOS, phatyngis NOS, phatyngi	ed terms): dyscept at irritation; upper antition (St.), borth assets, part assetting (St.), borth assets, part assets (St.), borth assets (St.	1.7 to stops and is resolutioner than resolutioner than resolutioner than resolutioner than solution signs and of the resolution of published that are presented as are presented in the major than to make the resolution of the r	1.0 emptone (dyses) infections such infections in Table 2. In the SWeeks and Sweeks and Melecticam 7.3 mg daily 126.6 4.7 1.8 6.9 2.0 4.7 1.8 0.8 2.4 2.6 2.4 2.5 5.6	2.1 cota, typoposo open unspecification and as the second of the second
Headaches NOS* Skin and Sahoubaseau Troma Bloom Rosh NOS* MedORA, high level term (preferre against year, restation, pathodrechi, chrysglis NOS, phatyngis NOS, singlesswide, joint or authodrechi, chrysglis NOS, phatyngis NOS, phaty	ed ferms): dyscepled in interest nit property of the control of th	1.7 1.7 1.6 styre and is resistance to the second of the	1.0 Inflortence (dyses inflortence cosh symptoms (artists) symptoms (artists) symptoms (artists) and (artists) symptoms (artists) and (artists) artists (ar	2.1 cotals, dyspension open unspecification, archeals, archeals, and reals Mills 6 works) at 16 North Active relied Triefs. NationScena 16 mg daily 24.2 2.9 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
Headaches NOS* Sain and Sahoubaneaus Thomas Bloom Rosh NOS* MedDRA high level form (preferre approving, created an, pathodrech, changed in NOS, phatyngide NOS	ed ferms): dyscept at inhabitation, upper matter MSS, to rit assets, part assetting matter matter MSS, to rit assets, part assetting matter ma	1.7 Iso stops and so recognized by the constitution of published signs and of the constitution of published signs and of the constitution of published signs are constitution as the constitution of published signs are constitution of the constitut	1.0 Inflictions (dyses) inflictions cather sections supplements (after sections supplements (after sections sections (after sections sections (after sections sections sections (after sections sections sections sections sections (after sections s	2.1 cotal, typepers open unspecification and the first of the cotal through a referral to the cotal through a referral through a referra
Headaches NOS* Skin and Sahoubaness Trome Older Rosh NOS* Machine Head Trome Older Rosh NOS Headaches Headache Juring Is NOS, pharyogis Nosabharia (No Constitution Trials) Ha. of Patiente Gastrantestinal Abdominal path Constitution Diarrice Dysoposis Raticiero Nosabe Veniting Body as a Whalie Activity Nosabharia Pharyogis Castral and Partylesod Merwase Spatian Diarrices Headaches Headaches Headaches Headaches Headaches Headaches Mermaticipte Anaritis Messalosskaletal Activity Nosabharia Incomma	ed terms): dyscept and intradent, upper matter MSS, borth assets, most awarding most a	1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7	1.0 Inflictions (dyses inflictions such symptoms (artists) symptoms (artists) symptoms (artists) in Table 2. Inflictions (artists) in Table 2. Inflictions (artists) and (artists) artists (a	2.1 cotia, typeness open unspecifications and reach Miles 88, and reach Miles 16 North Active reflect Triefs Nelcotcom 16 mg daily 24 2 9 2 6 9 2 6 9 2 6 9 2 6 7 2 6 9 7 2 6 7 2 6 7 2 7 2 6 7 2 7 2 8 7 2 8 7 2 8 7 2 8 7 2 8 7 2 8 7 2 8 7 2 8 7 2 8 7 2 8 7 8 7
Headaches NOS Sain and Sahoubaneaus Trome Otos Rosh NOS Rosh	ed terms): dyscept and intradent, upper matter MSS, term is several matter MSS in Melandeam in 29 terms of Melandeam in 25 terms of Melan	1.7 1.7 1.0 o signs and is a resolution of the constitution of the constitution of the constitution of the constitution of patient of the constitution of the constitu	1.0 Inflictions (dyses inflictions such symptoms (artists) symptoms (artists) symptoms (artists) in Table 2. Inflictions (artists) in Table 2. Inflictions (artists) and (artists) artists (a	2.1 cotia, typoposic popularizacia, archiala popularizacia, archiala para archiala par
Headaches NOS Sain and Sahouhaneau Trome Oton Rosh NOS MedORA, high level term (preferre aggrowted, credition, pastrohecti (dryngitis NOS, pharyngitis NOS, si aggrowted, credition, pastrohecti (dryngitis NOS, pharyngitis NOS, si aggrowted, pastrohecti (dryngitis NOS, pharyngitis NOS, si aggrowted, pastrohecti ModORA, preferred term: nacea, and ModORA, preferred term: nacea, and modorate extent and occurred with any-term (if modifis) in active-contro- fable 2 Africane Events (%) Occurring bashcolled Ostananthelitis Trials He. of Patients Gastrohetestinal Addominal path Constitution Distribution Distribution Distribution Roshing Body as a Whole Activitied Body as a Whole Activitied Memorial path Control Distribution Distribution Distribution Roshing Rosk poin Psychiatris Instrume Rospitationy Coughing Coughing Coughing	ed terms): dyscept at irritation; upper attacks (NS), torti asset, part assetting (NS), torti asset, part	1.7 to stops and 1.7 to	1.0 emptone (dyses) infections such infections in Table 2. In the 6 Weeks and 1.8 E.9 S.0 4.7 1.8 E.9 S.0 4.7 1.8 C.9 S.0 4.7 1.8 C.9 S.0 4.7 1.8 C.9 S.0 5.0 4.7 1.8 C.9 S.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5	2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1
Headaches NOS* Sain and Sahoubaneaus Trome Otom Rosh NOS* MedORA high level term (preferre approving, cracted an, pathodrech, (brings its NOS, phatyngis NOS	ed terms): dyscept and intradent, upper matter MSS, term is several matter MSS in Melandeam in 29 terms of Melandeam in 25 terms of Melan	1.7 1.7 1.0 o signs and is a resolution of the constitution of the constitution of the constitution of the constitution of patient of the constitution of the constitu	1.0 Inflictions (dyses inflictions such symptoms (artists) symptoms (artists) symptoms (artists) in Table 2. Inflictions (artists) in Table 2. Inflictions (artists) and (artists) artists (a	2.1 cotia, typoposic popularizacia, archiala popularizacia, archiala para archiala par
Headaches NOS* Sain and Sahoubaness Trome Otos Rosh NOS* March Sahoubaness Trome Otos Rosh NOS* MedORA, high level term (preferre aganovade, cractation, patrointectin (during the NOS, pharyagits NOS, si aganovade, in cractation, patrointectin (during the NOS, pharyagits NOS, si aganovade, in cractation, patrointectin MedORA, preferred terms nasses, and headaces executes that occurred with any-term (is monthel) in active-contre table 2 Africance Events (%) Department table 2 Africance Events (%) Department Castrointectinal Adorminal patro Constitution Diarrice Dyspeps is Ratulance Memors Veneting Body as a Whatie Actident Incominal Estama Phin Control and Partphend Memors State Hemestatiogic Anactis Messesiosistalistal Activitios Inscrime Respiratory Coughing Upper respiratory (sect in feetion State State State Department State	d ferms): dyscept at intraction, upon at intraction, upon attention with the second attention with the second attention with the second attention at a second attention atte	1.7 1.7 1.0 big signs and is a resolution of the constitution of t	1.0 Inflortions (dyses inflortions such symptoms (artist) symptom	2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1
Headaches NOS Sain and Sahoubaneaus Trome Otos Rosh NOS Rosh NOS MedORA, high level form (preform aganwated, credation, past-bidecel (darying to NOS), pharying to NOS, pharying to NOS pharying to Nos device several state occurred with broadwate several state occurred victorial participation. Nos of Patients Gastriantestinal Advantiral path Constitution Darthes Dyspeps is Estudence Noses Versiting Body as a Whole Actional Edman Phin Control of Participation Morrison Headache Headachestinal Advantiral Francisco Headachestinal Advantiral Francisco Headachestinal Advantiral Francisco Headachestinal Actional Francisco Headachestinal Arthroligis Reception Reception Reception Respiratory Coughing Upper reception to text in textion Skill Printins	d terms): dyscept at intradent, upper and intradent, upper and in MoS, in and interest MoS, in and interest MoS, in an area in MoS, in MoS in	1.7 1.7 1.0 c signs and is resolvance that resolvance that resolvance that resolvance that resolvance that signs and of the resolvance that is the sign and the resolvance that are presented in 15 mg daily 256 18.0 2.3 1.2 2.7 7.4 0.4 4.7 0.8 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	1.0 Inflictions (dyses inflictions spik) inflictions spik symptoms (artists, head caches Mcd short term (4) in Table 2. It to 6 Weeks and 5.4 mg deliy 1893 25.6 4.7 1.8 6.9 2.0 4.7 1.8 6.9 2.0 4.7 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 8.3	2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1
Headaches NOS* Sain and Sahoubaness Trome Otos Rosh NOS* March Sahoubaness Trome Otos Rosh NOS* MedORA, high level term (preferre aganovade, cractation, patrointectin (during the NOS, pharyagits NOS, si aganovade, in cractation, patrointectin (during the NOS, pharyagits NOS, si aganovade, in cractation, patrointectin MedORA, preferred terms nasses, and headaces executes that occurred with any-term (is monthel) in active-contre table 2 Africance Events (%) Department table 2 Africance Events (%) Department Castrointectinal Adorminal patro Constitution Diarrice Dyspeps is Ratulance Memors Veneting Body as a Whatie Actident Incominal Estama Phin Control and Partphend Memors State Hemestatiogic Anactis Messesiosistalistal Activitios Inscrime Respiratory Coughing Upper respiratory (sect in feetion State State State Department State	d ferms): dyscept at intraction, upon at intraction, upon attention with the second attention with the second attention with the second attention at a second attention atte	1.7 1.7 1.0 big signs and is a resolution of the constitution of t	1.0 Inflortions (dyses inflortions such symptoms (artist) symptom	2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1
Headaches NOS Sain and Sakoulaseasas Torase Olice Rosh NOS MedDRA high level term (proferra aggravand, cracted an, post-intectin (during the NOS, photyroigh NOS, sing- aggravand, and cracted an, post-intectin (during the NOS, photyroigh NOS, sing- aggravand, and cracted an, post-intectin post-interest transport of the notion of the salvand centre of the salvand centre of the salvand and the sa	d terms): dyscept at intradent, upper and intradent, upper and in MoS, in and interest MoS, in and interest MoS, in an area in MoS, in MoS in	1.7 1.7 1.0 c signs and is resolvance that resolvance that resolvance that resolvance that resolvance that signs and of the resolvance that is the sign and the resolvance that are presented in 15 mg daily 256 18.0 2.3 1.2 2.7 7.4 0.4 4.7 0.8 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	1.0 Inflictions (dyses inflictions spik) inflictions spik symptoms (artists, head caches Mcd short term (4) in Table 2. It to 6 Weeks and 5.4 mg deliy 1893 25.6 4.7 1.8 6.9 2.0 4.7 1.8 6.9 2.0 4.7 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.9 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 7.1 1.8 6.8 2.4 8.3	2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1

Higher doses of meloxicam (22.5 mg and greater) have been associated with an

increased risk of serious GI events; therefore, the daily dose of meloxicam should not exceed 15 mg.

Pediatrics

Pauciarticular and Polyarticular Course Juvenile Rheumatoid Arthritis (JRA)

Three hundred and eighty-seven patients with pauciarticular and polyarticular course JRA were exposed to Meloxicam with doses ranging from 0.125 to 0.375 mg/kg per day in three clinical trials. These studies consisted of two 12-week multicenter, double-blind, randomized trials (one with a 12-week open-label extension and one with a 40-week extension) and one 1-year open-label PK study. The adverse events observed in these pediatric studies with Meloxicam were similar in nature to the adult clinical trial experience, although there were differences in frequency. In particular, the following most common adverse events, abdominal pain, vomiting, diarrhea, headache, and pyrexia, were more common in the pediatric than in the adult trials. Rash was reported in seven (<2%) patients receiving Meloxicam. No unexpected adverse events were identified during the course of the trials. The adverse events did not demonstrate an age or gender-specific subgroup effect.

The following is a list of adverse drug reactions occurring in <2% of patients receiving Meloxicam in clinical trials involving approximately 16,200 patients.

Body as a Whole	allergic reaction, face edema, fatigue, fever, hot flushes, malaise, syncope, weight decrease, weight increase		
Cardiovascular	angina pectoris, cardiac failure, hypertension, hypotension, myocardial infarction, vasculitis		
Central and Peripheral Nervous System	convulsions, paresthesia, tremor, vertigo		
Gastrointestinal	colitis, dry mouth, duodenal ulcer, eructation, esophagitis, gastric ulcer, gastritis, gastroesophageal reflux, gastrointestinal hemorrhage, hematemesis, hemorrhagic duodenal ulcer, hemorrhagic gastric ulcer, intestinal perforation, melena, pancreatitis, perforated duodenal ulcer, perforated gastric ulcer, stomatitis ulcerative		
Heart Rate and Rhythm	arrhythmia, palpitation, tachycardia		
Hematologic	leukopenia, purpura, thrombocytopenia		
Liver and Biliary System	ALT increased, AST increased, bilirubinemia, GGT increased, hepatitis		
Metabolic and Nutritional	dehydration		
Psychiatric	abnormal dreaming, anxiety, appetite increased, confusion, depression, nervousness, somnolence		
Respiratory	asthma, bronchospasm, dyspnea		
Skin and Appendages	alopecia, angioedema, bullous eruption, photosensitivity reaction, pruritus, sweating increased, urticaria		
Special Senses	abnormal vision, conjunctivitis, taste perversion, tinnitus		
Urinary System	albuminuria, BUN increased, creatinine increased, hematuria, renal failure		

6.2 Post Marketing Experience

The following adverse reactions have been identified during post approval use of Meloxicam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions about whether to include an adverse event from spontaneous reports in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) number of reports, or (3) strength of causal relationship to the drug. Adverse reactions reported in worldwide post marketing

experience or the literature include: acute urinary retention; agranulocytosis; alterations in mood (such as mood elevation); anaphylactoid reactions including shock; erythema multiforme; exfoliative dermatitis; interstitial nephritis; jaundice; liver failure; Stevens-Johnson syndrome; toxic epidermal necrolysis, and infertility female.

7 DRUG INTERACTIONS

See Table 3 for clinically significant drug interactions with meloxicam. See also *Warnings* and *Precautions* (5.2, 5.6, 5.11) and *Clinical Pharmacology* (12.3).

Table 3 Clinically Significant Drug Interactions with Meloxicam

	with Hemostasis
Olinical Impact:	 Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotoni release by platelets plays an important role in hemostasis. Case-contri and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.
Intervention:	Monitor patients with concomitant use of Meloxicam with anticoagulants (e.g., warfarin), antiplateit agents (e.g., apprint), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (S.11)].
Aspirin	(6)
Ofinical Impact:	Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2)].
intervention:	Concomitant use of Meloxicam and low dose aspirin or analysesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Wavnings and Precautions (α.111)]. Meloxicam is not a substitute for low dose aspirin for cardiovascular protection.
ACE Inhibitore Ana	folensin Receptor Blockers, or Beta-Blockers
Clinical Impact:	NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranciol). In patients who are elderly, volume-depleted (including those on diuretic therapy or have reral impairment, coadministration of an NSAID with ACE inhibitors or ARBs may result in descripation of renal function, including possible acute renal failure. These effects are usually reversible.
Intervention:	During concomitant use of Meloxicam and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. During concomitant use of Meloxicam and ACE inhibitors or ARBs in patients whare elderly, volume-depieted, or have impaired renal function, monitor for signs worsening renal function [see Warnings and Precautions (5.6)]. When these drugs are administered concomitantly, patients should be adequated hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.
Diuretics	
Oinical Impact:	Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thicatide diuretics in some patients. This effect has been aftiributed to the NSAID inhibition of renal prostaglandin synthesis. However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam.
Intervention:	During concomitant use of Meloxicam with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6)].
Lithium	
Clinical Impact:	NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis [see Clinical Pharmacology (12.3)].
Intervention:	During concomitant use of Meloxicam and lithium, monitor patients for signs of lithium toxicity.
Methotrexate	
Offical Impact: Intervention:	Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).
intervention:	During concomitant use of Meloxicam and methotrexate, monitor patients for methotrexate toxicity.
Cyclesporine	
Ofinical Impact:	Concomitant use of Meloxicam and cyclosporine may increase cyclosporine's nephrotoxicity.
Intervention:	During concomitant use of Meloxicam and cyclosporine, monitor patients for signs of worsening renal function.
NSAIDs and Salicyl	
Ofinical Impact:	Concomitant use of meloxicam with other NSAIDs or salicylates (e.g., diffunisal, salisalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2)].
Intervention:	The concomitant use of meloxicam with other NSAIDs or salicylates is not recommended.
Pemetrexed	
Clinical Impact:	Concomitant use of Meloxicam and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).
Intervention:	During concomitant use of Meloxicam and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.
	Patients taking meloxicam should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
	In patients with creatinine clearance below 45 mL/min, the concomitant

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Use of NSAIDs, including Meloxicam, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including Meloxicam, in pregnant women starting at 30 weeks of gestation (third trimester) [see Warnings and Precautions (5.10)].

There are no adequate and well-controlled studies of Meloxicam in pregnant women. Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In the general U.S. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% for major malformations, and 15-20% for pregnancy loss.

In animal reproduction studies, embryofetal death was observed in rats and rabbits treated during the period of organogenesis with meloxicam at oral doses equivalent to 0.65- and 6.5-times the maximum recommended human dose (MRHD) of Meloxicam. Increased incidence of septal heart defects were observed in rabbits treated throughout embryogenesis with meloxicam at an oral dose equivalent to 78-times the MRHD. In preand post-natal reproduction studies, there was an increased incidence of dystocia, delayed parturition, and decreased offspring survival at 0.08-times MRHD of meloxicam. No teratogenic effects were observed in rats and rabbits treated with meloxicam during organogenesis at an oral dose equivalent to 2.6 and 26-times the MRHD [see Data].

Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors, such as meloxicam, resulted in increased pre- and post-implantation loss.

Clinical Considerations

Labor or Delivery

There are no studies on the effects of Meloxicam during labor or delivery. In animal studies, NSAIDs, including meloxicam, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.

Data

Animal Data

Meloxicam was not teratogenic when administered to pregnant rats during fetal organogenesis at oral doses up to 4 mg/kg/day (2.6-fold greater than the MRHD of 15 mg of Meloxicam based on BSA comparison). Administration of meloxicam to pregnant rabbits throughout embryogenesis produced an increased incidence of septal defects of the heart at an oral dose of 60 mg/kg/day (78-fold greater than the MRHD based on BSA comparison). The no effect level was 20 mg/kg/day (26-fold greater than the MRHD based on BSA conversion). In rats and rabbits, embryolethality occurred at oral meloxicam doses of 1 mg/kg/day and 5 mg/kg/day, respectively (0.65 and 6.5-fold greater, respectively, than the MRHD based on BSA comparison) when administered throughout organogenesis.

Oral administration of meloxicam to pregnant rats during late gestation through lactation increased the incidence of dystocia, delayed parturition, and decreased offspring survival at meloxicam doses of 0.125 mg/kg/day or greater (0.08-times MRHD based on BSA comparison).

8.2 Lactation

Risk Summary

There are no human data available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Meloxicam and any potential adverse effects on the breastfed infant from the Meloxicam or from the underlying maternal condition.

Data

Animal Data

Meloxicam was present in the milk of lactating rats at concentrations higher than those in plasma.

8.3 Females and Males of Reproductive Potential

Infertility

Females

Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including Meloxicam, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including Meloxicam, in women who have difficulties conceiving or who are undergoing investigation of infertility.

8.4 Pediatric Use

The safety and effectiveness of meloxicam in pediatric JRA patients from 2 to 17 years of age has been evaluated in three clinical trials [see Dosage and Administration (2.3), Adverse Reactions (6.1) and Clinical Studies (14.2)].

8.5 Geriatric Use

Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.13)].

8.6 Hepatic Impairment

No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment have not been adequately studied. Since

meloxicam is significantly metabolized in the liver and hepatotoxicity may occur, use meloxicam with caution in patients with hepatic impairment [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

8.7 Renal Impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of Meloxicam in subjects with severe renal impairment is not recommended. In patients on hemodialysis, meloxicam should not exceed 7.5 mg per day. Meloxicam is not dialyzable [see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)].

10 OVERDOSAGE

Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [see Warnings and Precautions (5.1, 5.2, 5.4, 5.6)].

Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

There is limited experience with meloxicam overdosage. Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage.

For additional information about overdosage treatment, call a poison control center (1-800-222-1222).

11 DESCRIPTION

Meloxicam Tablets USP are a nonsteroidal anti-inflammatory drug (NSAID). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is $C_{14}H_{13}N_3O_4S_2$ and it has the following structural formula:

Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)_{app} = 0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2.

Meloxicam is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam.

The inactive ingredients in Meloxicam tablets USP include colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium citrate dihydrate.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Meloxicam has analgesic, anti-inflammatory, and antipyretic properties.

The mechanism of action of Meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

12.3 Pharmacokinetics

<u>Absorption</u>

The absolute bioavailability of meloxicam capsules was 89% following a single oral dose of 30 mg compared with 30 mg IV bolus injection. Following single intravenous doses,

dose-proportional pharmacokinetics were shown in the range of 5 mg to 60 mg. After multiple oral doses the pharmacokinetics of meloxicam capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean $C_{\rm max}$ was achieved within four to five hours after a 7.5 mg meloxicam tablet was taken under fasted conditions, indicating a prolonged drug absorption. With multiple dosing, steady-state concentrations were reached by Day 5. A second meloxicam concentration peak occurs around 12 to 14 hours post-dose suggesting biliary recycling.

Meloxicam capsules have been shown to be bioequivalent to Meloxicam tablets.

Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)¹.

			Steady State)	Sing	jle Dose
Pharmacokinetic Parameters (%CV)		Healthy male adults (Fed) ²	Elderly males (Fed) ²	Elderly females (Fed) ²	Renal failure (Fasted)	Hepatic insufficiency (Fasted)
		7.5 mg ³ tablets	15 mg capsules	15 mg capsules	15 mg capsules	15 mg capsules
N		18	5	8	12	12
C _{max}	[µg/mL]	1.05 (20)	2.3 (59)	3.2 (24)	0.59 (36)	0.84 (29)
t _{max}	[h]	4.9 (8)	5 (12)	6 (27)	4 (65)	10 (87)
t _{1/2}	[h]	20.1 (29)	21 (34)	24 (34)	18 (46)	16 (29)
CL/f	[mL/min]	8.8 (29)	9.9 (76)	5.1 (22)	19 (43)	11 (44)
V _z /f ⁴	[L]	14.7 (32)	15 (42)	10 (30)	26 (44)	14 (29)

¹ The parameter values in the table are from various studies

Food and Antacid Effects

Administration of meloxicam capsules following a high fat breakfast (75 g of fat) resulted in mean peak drug levels (i.e., C_{max}) being increased by approximately 22% while the extent of absorption (AUC) was unchanged. The time to maximum concentration (T_{max}) was achieved between 5 and 6 hours. No pharmacokinetic interaction was detected with concomitant administration of antacids. Based on these results, Meloxicam can be administered without regard to timing of meals or concomitant administration of antacids.

Distribution

The mean volume of distribution (Vss) of meloxicam is approximately 10 L. Meloxicam is \sim 99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to \sim 99% in patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than

² not under high fat conditions

³ Meloxicam tablets

⁴ V_z/f=Dose/(AUC•K_{el})

10%. Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam.

Meloxicam concentrations in synovial fluid, after a single oral dose, range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid as compared to plasma. The significance of this penetration is unknown.

Elimination

Metabolism

Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 5'-carboxy meloxicam (60% of dose), from P-450 mediated metabolism formed by oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of dose). *In vitro* studies indicate that CYP2C9 (cytochrome P450 metabolizing enzyme) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Patients' peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose, respectively. All the four metabolites are not known to have any *in vivo* pharmacological activity.

Excretion

Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6%, and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively. There is significant biliary and/or enteral secretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam by 50%.

The mean elimination half-life ($t_{1/2}$) ranges from 15 hours to 20 hours. The elimination half-life is constant across dose levels indicating linear metabolism within the therapeutic dose range. Plasma clearance ranges from 7 to 9 mL/min.

Specific Populations

Pediatric

After single (0.25 mg/kg) dose administration and after achieving steady state (0.375 mg/kg/day), there was a general trend of approximately 30% lower exposure in younger patients (2 to 6 years old) as compared to the older patients (7 to 16 years old). The older patients had meloxicam exposures similar (single dose) or slightly reduced (steady state) to those in the adult patients, when using AUC values normalized to a dose of 0.25 mg/kg [see Dosage and Administration (2.4)]. The meloxicam mean (SD) elimination half-life was 15.2 (10.1) and 13.0 hours (3.0) for the 2 to 6 year old patients, and 7 to 16 year old patients, respectively.

In a covariate analysis, utilizing population pharmacokinetics body-weight, but not age, was the single predictive covariate for differences in the meloxicam apparent oral plasma clearance. The body-weight normalized apparent oral clearance values were adequate predictors of meloxicam exposure in pediatric patients.

The pharmacokinetics of Meloxicam in pediatric patients under 2 years of age have not

been investigated.

Geriatric

Elderly males (\geq 65 years of age) exhibited meloxicam plasma concentrations and steady-state pharmacokinetics similar to young males. Elderly females (\geq 65 years of age) had a 47% higher AUC_{ss} and 32% higher C_{max},ss as compared to younger females (\leq 55 years of age) after body weight normalization. Despite the increased total concentrations in the elderly females, the adverse event profile was comparable for both elderly patient populations. A smaller free fraction was found in elderly female patients in comparison to elderly male patients.

Sex

Young females exhibited slightly lower plasma concentrations relative to young males. After single doses of 7.5 mg Meloxicam, the mean elimination half-life was 19.5 hours for the female group as compared to 23.4 hours for the male group. At steady state, the data were similar (17.9 hours vs 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the $C_{\rm max}$ or $T_{\rm max}$ across genders.

Hepatic Impairment

Following a single 15 mg dose of meloxicam there was no marked difference in plasma concentrations in patients with mild (Child-Pugh Class I) or moderate (Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein binding of meloxicam was not affected by hepatic impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)].

Renal Impairment

Meloxicam pharmacokinetics have been investigated in subjects with mild and moderate renal impairment. Total drug plasma concentrations of meloxicam decreased and total clearance of meloxicam increased with the degree of renal impairment while free AUC values were similar in all groups. The higher meloxicam clearance in subjects with renal impairment may be due to increased fraction of unbound meloxicam which is available for hepatic metabolism and subsequent excretion. No dosage adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been adequately studied. The use of Meloxicam in subjects with severe renal impairment is not recommended [see Dosage and Administration (2.5), Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].

Hemodialysis

Following a single dose of meloxicam, the free C_{max} plasma concentrations were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not necessary after hemodialysis. Meloxicam is not dialyzable [see Dosage and Administration (2.1) and Use in Specific Populations (8.7)].

Drug Interaction Studies

Aspirin: When NSAIDs were administered with aspirin, the protein binding of NSAIDs

were reduced, although the clearance of free NSAID was not altered. When Meloxicam is administered with aspirin (1000 mg three times daily) to healthy volunteers, it tended to increase the AUC (10%) and C_{max} (24%) of meloxicam. The clinical significance of this interaction is not known. See Table 3 for clinically significant drug interactions of NSAIDs with aspirin [see Drug Interactions (7)].

Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. This resulted in a decrease in $t_{1/2}$, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The clinical relevance of this interaction has not been established.

Cimetidine: Concomitant administration of 200 mg cimetidine four times daily did not alter the single-dose pharmacokinetics of 30 mg meloxicam.

Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after β -acetyldigoxin administration for 7 days at clinical doses. In vitro testing found no protein binding drug interaction between digoxin and meloxicam.

Lithium: In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 15 mg QD every day as compared to subjects receiving lithium alone [see Drug Interactions (7)].

Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. *In vitro*, methotrexate did not displace meloxicam from its human serum binding sites [see Drug Interactions (7)].

Warfarin: The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering Meloxicam with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced [see Drug Interactions (7)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

<u>Carcinogenesis</u>

There was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice (99 weeks) administered meloxicam at oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in mice (up to 0.5-and 2.6-times, respectively, the maximum recommended human dose [MRHD] of 15 mg/day Meloxicam based on body surface area [BSA] comparison).

<u>Mutagenesis</u>

Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome

aberration assay with human lymphocytes and an *in vivo* micronucleus test in mouse bone marrow.

<u>Impairment of Fertility</u>

Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 5.8- and 3.2-times greater, respectively, than the MRHD based on BSA comparison).

14 CLINICAL STUDIES

14.1 Osteoarthritis and Rheumatoid Arthritis

The use of Meloxicam for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, double-blind, controlled trial. Meloxicam (3.75 mg, 7.5 mg, and 15 mg daily) was compared to placebo. The four primary endpoints were investigator's global assessment, patient global assessment, patient pain assessment, and total WOMAC score (a self-administered questionnaire addressing pain, function, and stiffness). Patients on Meloxicam 7.5 mg daily and Meloxicam 15 mg daily showed significant improvement in each of these endpoints compared with placebo.

The use of Meloxicam for the management of signs and symptoms of osteoarthritis was evaluated in six double-blind, active-controlled trials outside the U.S. ranging from 4 weeks' to 6 months' duration. In these trials, the efficacy of Meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable to piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial.

The use of Meloxicam for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving Meloxicam 7.5 mg and 15 mg daily showed significant improvement in the primary endpoint compared with placebo. No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose.

14.2 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

The use of Meloxicam for the treatment of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older was evaluated in two 12-week, double-blind, parallel-arm, active-controlled trials.

Both studies included three arms: naproxen and two doses of meloxicam. In both studies, meloxicam dosing began at 0.125 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum), and naproxen dosing began at 10 mg/kg/day. One study used these doses throughout the 12-week dosing period, while the other incorporated a titration after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day (22.5 mg maximum) of meloxicam and 15 mg/kg/day of naproxen.

The efficacy analysis used the ACR Pediatric 30 responder definition, a composite of parent and investigator assessments, counts of active joints and joints with limited range

of motion, and erythrocyte sedimentation rate. The proportion of responders were similar in all three groups in both studies, and no difference was observed between the meloxicam dose groups.

16 HOW SUPPLIED/STORAGE AND HANDLING

Meloxicam Tablets USP are available as Light yellow, round flat beveled edge tablet with "T" on one side and "152" on the other side for 7.5 mg and Light yellow, capsule shaped biconvex tablet with "T" on one side and "153" on the other side for 15 mg.

Meloxicam Tablets USP 7.5 mg are available as follows:

NDC 72865-137-90; Bottles of 90

NDC 72865-137-01; Bottles of 100

NDC 72865-137-10; Bottles of 1000

Meloxicam Tablets USP 15 mg are available as follows:

NDC 72865-138-90; Bottles of 90

NDC 72865-138-01; Bottles of 100

NDC 72865-138-10; Bottles of 1000

Storage Store at 20⁰ to 25⁰C (68⁰ to 77⁰F) [See USP Controlled Room Temperature]. Keep Meloxicam Tablets USP in a dry place

Dispense tablets in a tight container.

Keep this and all medications out of the reach of children.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed.

Inform patients, families or their caregivers of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy.

Cardiovascular Thrombotic Events

Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their healthcare provider immediately [see Warnings and Precautions (5.1)].

Gastrointestinal Bleeding, Ulceration, and Perforation

Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their healthcare provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of GI bleeding [see Warnings and Precautions (5.2)].

Hepatotoxicity

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flulike" symptoms). If these occur, instruct patients to stop Meloxicam tablets and seek immediate medical therapy [see Warnings and Precautions (5.3)].

Heart Failure and Edema

Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see Warnings and Precautions (5.5)].

<u>Anaphylactic Reactions</u>

Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [see Contraindications (4) and Warnings and Precautions (5.7)].

Serious Skin Reactions

Advise patients to stop Meloxicam tablets immediately if they develop any type of rash and to contact their healthcare provider as soon as possible [see Warnings and Precautions (5.9)].

Female Fertility

Advise females of reproductive potential who desire pregnancy that NSAIDs, including Meloxicam tablets, may be associated with a reversible delay in ovulation [see Use in Specific Populations (8.3)].

Fetal Toxicity

Inform pregnant women to avoid use of Meloxicam tablets and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus [see Warnings and Precautions (5.10) and Use in Specific Populations (8.1)].

Avoid Concomitant Use of NSAIDs

Inform patients that the concomitant use of Meloxicam tablets with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [see Warnings and Precautions (5.2) and Drug Interactions (7)]. Alert patients that NSAIDs may be present in "over the counter" medications for treatment of colds, fever, or insomnia.

Use of NSAIDs and Low-Dose Aspirin

Inform patients not to use low-dose aspirin concomitantly with Meloxicam tablets until they talk to their healthcare provider [see Drug Interactions (7)].

Please address medical inquiries to 1-866-495-1995

Manufactured by:

Ascent Pharmaceuticals, Inc.

Central Islip, NY 11722

Manufactured for:

XLCare Pharmaceuticals, Inc.

242 South Culver Street, Suite 202

Lawrenceville, GA 30046.

Rev: 02/21

Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
What is the most important information I should know about medicines
called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?
NSAIDs can cause serious side effects, including:

- Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase:
- with increasing doses of NSAIDs
- with longer use of NSAIDs

Do not take NSAIDs right before or after a heart surgery called a "coronary artery bypass graft (CABG)."

Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.

- Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:
 - o anytime during use
 - o without warning symptoms
 - o that may cause death

The risk of getting an ulcer or bleeding increases with:

- o past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs
 - o taking medicines called "corticosteroides", "anticoagulants", "SSRIs", or "SNRIs"
 - o increasing doses of NSAIDs o older age o longer use of NSAIDs o poor health
 - o smoking o advanced liver disease o drinking alcohol o bleeding problems

NSAIDs should only be used:

- o exactly as prescribed
- o at the lowest dose possible for your treatment
- o for the shortest time needed

What are NSAIDs?

NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain.

Who should not take NSAIDs? Do not take NSAIDs:

- if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs.
- right before or after heart bypass surgery.

Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you:

- have liver or kidney problems
- have high blood pressure
- have asthma
- are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy. You should not take NSAIDs after 29 weeks of pregnancy.
- are breastfeeding or plan to breast feed.

Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. NSAIDs and some other medicines can interact with each other and cause serious side effects. Do not start taking any new medicine without talking to your healthcare provider first.

What are the possible side effects of NSAIDs?

NSAIDs can cause serious side effects, including:

See "What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?"

- new or worse high blood pressure
- heart failure
- liver problems including liver failure
- kidney problems including kidney failure
- low red blood cells (anemia)
- life-threatening skin reactions
- life-threatening allergic reactions
- Other side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness

Get emergency help right away if you get any of the following symptoms:

- shortness of breath or trouble breathing
- chest pain
- weakness in one part or side of your body
- slurred speech
- swelling of the face or throat

Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:

- nausea
- more tired or weaker than usual or it is black and sticky like tar
- diarrhea
- itching
- your skin or eyes look yellow feet
- indigestion or stomach pain
- flu-like symptoms

- vomit blood
 - there is blood in your bowel movement
- unusual weight gain
- skin rash or blisters with fever
 - swelling of the arms, legs, hands and

If you take too much of your NSAID, call your healthcare provider or get medical help right away.

These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Other information about NSAIDs:

- Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.
- Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk
 to your healthcare provider before using over-the-counter NSAIDs for more than 10
 days.

General information about the safe and effective use of NSAIDs

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them.

If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by:

Ascent Pharmaceuticals, Inc.

Central Islip, NY 11722

Manufactured for:

XLCare Pharmaceuticals, Inc.

242 South Culver Street, Suite 202

Lawrenceville, GA 30046

Rev: 02/20

Repackaging Information

Please reference the **How Supplied** section listed above for a description of individual tablets. This drug product has been received by Aphena Pharma - TN in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations. The package configurations available from Aphena are listed below:

Count	15 mg
30	71610-544-30
60	71610-544-53
90	71610-544-60

Store between 20°-25°C (68°-77°F). See USP Controlled Room Temperature. Dispense in a tight light-resistant container as defined by USP. Keep this and all drugs out of the reach of children.

Repackaged by:




Cookeville, TN 38506

20210524JH

PRINCIPAL DISPLAY PANEL - 15 mg

NDC 71610-544 - Meloxicam, USP 15 mg Tablets - Rx Only



MELOXICAM

meloxicam tablet

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:71610-544(NDC:72865- 138)	
Route of Administration	ORAL			

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
MELOXICAM (UNII: VG2QF83CGL) (MELOXICAM - UNII:VG2QF83CGL)	MELOXICAM	15 mg		

Inactive Ingredients	
Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	

CROSPOVIDONE (UNII: 2S7830E561)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
POVIDONE (UNII: FZ989GH94E)	
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)	

Product Characteristics				
Color	YELLOW (Light Yellow)	Score	no score	
Shape	CAPSULE (Biconvex)	Size	11mm	
Flavor		Imprint Code	T;153	
Contains				

P	Packaging					
#	Item Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:71610-544- 30	30 in 1 BOTTLE; Type 0: Not a Combination Product	05/13/2021			
2	NDC:71610-544- 53	60 in 1 BOTTLE; Type 0: Not a Combination Product	07/26/2021			
3	NDC:71610-544- 60	90 in 1 BOTTLE; Type 0: Not a Combination Product	04/15/2021			

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA077927	02/17/2020		

Labeler - Aphena Pharma Solutions - Tennessee, LLC (128385585)

Establishment						
Name	Address	ID/FEI	Business Operations			
Aphena Pharma Solutions - Tennessee, LLC		128385585	REPACK(71610-544)			

Revised: 8/2021 Aphena Pharma Solutions - Tennessee, LLC